SCHEMBL1364563

SCHEMBL1364563

COc1c(CN(C(=O)O)C(C)(C)C)cccc1-c1cccc(CO[Si](C)(C)C(C)(C)C)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.38
TSHR P16473 3/20 0.38
NPSR1 Q6W5P4 3/20 0.38
GAA P10253 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.35
HTT P42858 1/20 0.35
FFAR1 O14842 2/20 0.35
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
ACHE P22303 3/20 0.34
PTGER1 P34995 1/20 0.34
PTGER4 P35408 1/20 0.34
PTGER3 P43115 1/20 0.34
PTGER2 P43116 1/20 0.34
PDCD1 Q15116 7/20 0.34
CD274 Q9NZQ7 7/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1362144 0.88 CD274 (0.41) LMNAFFAR1PTGER1PTGER4PTGER3
SCHEMBL1362264 0.87 FFAR1 (0.34) LMNATSHRNPSR1ALDH1A1KDM4E
SCHEMBL4088107 0.82 PDCD1 (0.41) FFAR1PDCD1CD274MEN1KMT2A
SCHEMBL1362409 0.82 LMNA (0.41) LMNATSHRNPSR1ALDH1A1HTT
SCHEMBL1363225 0.80 TSHR (0.46) LMNATSHRNPSR1GAASMN1; SMN2
SCHEMBL3427833 0.80 HTR7 (0.34) FFAR1PTGER1PTGER4PTGER3PTGER2
SCHEMBL3399261 0.78 BRD4 (0.43) HSD17B10PDCD1CD274
SCHEMBL1363398 0.78 MEN1 (0.39) LMNATSHRNPSR1GAASMN1; SMN2
SCHEMBL1363777 0.77 GRM2 (0.37) LMNATSHRNPSR1GAASMN1; SMN2
SCHEMBL3396510 0.74 CTSA (0.36) FFAR1PDCD1CD274CTSA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8071588-B2 Dual pharmacophores—PDE4-muscarinic antagonistics GLAXO GROUP LIMITED (GB) 2011-12-06 US disclosed
US-8067408-B2 Dual pharmacophores—PDE4-muscarinic antagonistics GLAXO GROUP LIMITED (GB) 2011-11-29 US disclosed
US-20090203677-A1 Dual Pharmacophores - PDE4-Muscarinic Antagonistics GLAXO GROUP LIMITED (GB) 2009-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203677-A1 Dual Pharmacophores - PDE4-Muscarinic Antagonistics PDE4A, PDE4B, PDE1A LMNA 4824/4885TSHR 2470/4885NPSR1 926/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.